

I hereby certify that this correspondence is being sent by facsimile
transmission to: Examiner Michael V. Meller at Fax No. 703-308-0294.

PATENT
Attorney Docket No.: 20695C-003100US
Client Ref. No.: WM-206.00

TOWNSEND and TOWNSEND and CREW LLP

By: Karen Lovino
Karen Lovino

#14/100
11-29-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

REDL *et al.*

Application No.: 09/486,516

Filed: February 28, 2000

For: FIBRINOGEN-BASED TISSUE
ADHESIVE CONTAINING AN
ELASTASE INHIBITOR

Examiner: Michael V. Meller

Art Unit: 1651

**RESPONSE TO RESTRICTION
REQUIREMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to Restriction Requirement mailed October 3, 2001, Applicants elect to prosecute Group I, claims 29-60 and 70-73, drawn to a tissue adhesive and a method of using it. Applicants also elect, with traverse, the following species: Claim 30: eglin; claims 33-35: fibrinogen; claim 40 or 43: with plasminogen; claim 45: none; claim 47: gentamycin; and claim 53: collagen. *affable*

The foregoing election is made with traverse, as the two groups set forth by the Examiner all stem from a common concept and theory, and are thus related. As such, prosecution of the claims of Groups I-II would not place a substantially greater burden on the Examiner. Applicants therefore respectfully request that the Examiner withdraw the Restriction Requirement and consider all the claims together.

Respectfully submitted,

Annette S. Parent

Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200; Fax: (415) 576-0300
SF 1295398 v1